NEW YORK, June 21, 2018 (GLOBE NEWSWIRE) -- Mid-Atlantic Bio Angels (MABA) announces today that Bonbouton, a New York-based company developing insole sensor technology to more rapidly identify circulatory conditions leading to diabetic foot ulcers, was named “Best in Show” at MABA's 1st Pitch Life Science event held on June 11, 2018 at Mt. Sinai Medical Center in New York.
“I have been attending the 1st Pitch Life Science event series since first working with NYCEDC via the ELab for Life Science Entrepreneurship program in New York City and have been impressed with the quality of feedback from the MABA team and the panel,” said Linh Le, founder & CEO of Bonbouton. “It was truly an honor to have the opportunity to showcase Bonbouton’s solution with the life science focused audience and receive constructive feedback to tailor a better value proposition for physicians.”
Bonbouton is currently developing smart insole technology with patented graphene sensors to detect circulatory conditions leading to foot ulcers in diabetic patients so that earlier clinical intervention can occur. The company’s insoles and connected platform continuously monitor foot temperature to provide an early signal of developing foot ulcers, thus enabling earlier preventive treatment. The feedback from the wearable and unobtrusive technology can significantly reduce the cost of care and provide better patient outcomes. With 25 percent of diabetic patients at risk for developing foot ulcers, the company anticipates its technology can serve as a preventive tool for all diabetic patients.
"Technologies that enable remote patient monitoring, such as those that effectively integrate medical diagnostics with software, will likely play an important role in the ongoing shift toward value-based healthcare,” said Jon Popke, a member of Mid Atlantic Bio Angels and one of the investor panelists. “It is great to see companies like Bonbouton working on solutions that could someday benefit diabetic patients and healthcare providers alike."
About 1st Pitch Life Science
At a 1st Pitch event (http://www.1stpitchlifescience.com), early stage life sciences and healthcare companies make a 15-minute presentation to a panel of experienced life science investors and consultants, followed by a 15-minute audience Q&A. However, where actual investors would then ask the presenting company to leave the room during their subsequent discussion, presenting companies at 1st Pitch are invited to hear the panel constructively critique the company's presentation, business model and perceived viability in the market.
Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA's goal is to create an environment where the depth of investors' knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.
JQA Partners, Inc.